Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase

European Journal of Pharmacology

Volumn 572, Issue 1, 2007, Pages 12-22

  Dunkern, Torsten R ^a   Feurstein, Daniel ^b   Rossi, Giovanni A ^c   Sabatini, Federica ^c   Hatzelmann, Armin ^a  

^a ALTANA PHARMA AG   (Germany)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

Fibrosis; Lung fibroblast; Phosphodiesterase; Sildenafil; TGF

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; ALPHA SMOOTH MUSCLE ACTIN; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; GUANYLATE CYCLASE ACTIVATOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PICLAMILAST; PROSTAGLANDIN E2; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; INHIBITION KINETICS; LUNG FIBROBLAST; LUNG FIBROSIS; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACTINS; BENZAMIDES; BENZOIC ACIDS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLIC GMP; DINOPROSTONE; DRUG SYNERGISM; ENZYME ACTIVATORS; FIBROBLASTS; FIBROSIS; GUANYLATE CYCLASE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LUNG; MYOCYTES, SMOOTH MUSCLE; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; OXADIAZOLES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; PYRIDINES; QUINOXALINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 34548498378     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.06.036     Document Type: Article

References (43)

1. Adler K.B., Low R.B., Leslie K.O., Mitchell J., and Evans J.N. Contractile cells in normal and fibrotic lung. Lab. Invest. 60 (1989) 473-485
2. Bauer A.C., and Schwabe U. An improved assay of cyclic 3′,5′-nucleotide phosphodiesterases with QAE-Sephadex columns. Naunyn-Schmiedeberg's Arch. Pharmacol. 311 (1980) 193-198
3. Borbe H.O., Hilboll G., and Prop G. Inhibition of human platelet aggregation by motapizone via an increase in intracellular cAMP. Agents Actions Suppl. 20 (1986) 249-257
4. Broekelmann T.J., Limper A.H., Colby T.V., and McDonald J.A. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 6642-6646
5. De Boer W.I., van Schadewijk A., Sont J.K., Sharma H.S., Stolk J., Hiemstra P.S., and van Krieken J.H. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 58 (1998) 1951-1957
6. Evgenov O.V., Ichinose F., Evgenov N.V., Gnoth M.J., Falkowsk G.E., Chang Y., Bloch K.D., and Zapol W.M. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110 (2004) 2253-2259
7. Ferrini M.G., Kovanecz I., Nolazco G., Rajfer J., and Gonzalez-Cadavid N.F. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int. 97 (2006) 625-633
8. Francis S.H., Turko I.V., and Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65 (2001) 1-52
9. Gabbiani G., and Badonnel M.C. Contractile events during inflammation. Agents Actions 6 (1976) 277-280
10. Grotendorst G.R., Rahmanie H., and Duncan M.R. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J. 18 (2004) 469-479
11. Gu L., Zhu Y.J., Guo Z.J., Xu X.X., and Xu W.B. Effect of IFN-gamma and dexamethasone on TGF-beta1-induced human fetal lung fibroblast-myofibroblast differentiation. Acta Pharmacol. Sin. 25 (2004) 1479-1488
12. Hatzelmann A., and Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297 (2001) 267-279
13. Kang T.S., Gorti G.K., Quan S.Y., Ho M., and Koch R.J. Effect of hyperbaric oxygen on the growth factor profile of fibroblasts. Arch. Facial Plast. Surg. 6 (2004) 31-35
14. Kapoun A.M., Liang F., O'Young G., Damm D.L., Quon D., White R.T., Munson K., Lam A., Schreiner G.F., and Protter A.A. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. 94 (2004) 453-461
15. Khalil N., O'Connor R.N., Unruh H.W., Warren P.W., Flanders K.C., Kemp A., Bereznay O.H., and Greenberg A.H. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 5 (1991) 155-162
16. Khalil N., O'Connor R.N., Flanders K.C., and Unruh H. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am. J. Respir. Cell. Mol. Biol. 14 (1996) 131-138
17. Kohyama T., Liu X., Wen F.Q., Zhu Y.K., Wang H., Kim H.J., Takizawa H., Cieslinski L.B., Barnette M.S., and Rennard S.I. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am. J. Respir. Cell. Mol. Biol. 26 (2002) 694-701
18. Kohyama T., Liu X., Wen F.Q., Kobayashi T., Fang Q., Abe S., Cieslinski L., Barnette M.S., and Rennard S.I. Cytokines modulate cilomilast response in lung fibroblasts. Clin. Immunol. 111 (2004) 297-302
19. Kolodsick J.E., Peters-Golden M., Larios J., Toews G.B., Thannickal V.J., and Moore B.B. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mol. Biol. 29 (2003) 537-544
20. Kraft P.J., Haynes-Johnson D., Bhattacharjee S., Lundeen S.G., and Qiu Y. Altered activities of cyclic nucleotide phosphodiesterases and soluble guanylyl cyclase in cultured RFL-6 cells. Int. J. Biochem. Cell Biol. 36 (2004) 2086-2095
21. Leask A., and Abraham D.J. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem. Cell. Biol. 81 (2003) 355-363
22. Lee A.J., Chiao T.B., and Tsang M.P. Sildenafil for pulmonary hypertension. Ann. Pharmacother. 39 (2005) 869-884
23. Li P., Oparil S., Novak L., Cao X., Shi W., Lucas J., and Chen Y.F. ANP signaling inhibits TGF-beta-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. J. Appl. Physiol. 102 (2007) 390-398
24. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005) 167-175
25. Liu X., Sun S.Q., Hassid A., and Ostrom R.S. cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. Mol. Pharmacol. 70 (2006) 1992-2003
26. Mapel D.W., Samet J.M., and Coultas D.B. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest 110 (1996) 1058-1067
27. Marshall R.P., Gohlke P., Chambers R.C., Howell D.C., Bottoms S.E., Unger T., McAnulty R.J., and Laurent G.J. Angiotensin II and the fibroproliferative response to acute lung injury. Am. J. Physiol., Lung Cell. Mol. Physiol. 286 (2004) 156-164
28. Martin-Chouly C.A., Astier A., Jacob C., Pruniaux M.P., Bertrand C., and Lagente V. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci. 75 (2004) 823-840
29. Pardo A., and Selman M. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int. J. Biochem. Cell Biol. 34 (2002) 1534-1538
30. Rabe K.F., Tenor H., Dent G., Schudt C., Liebig S., and Magnussen H. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am. J. Physiol. 264 (1993) 458-464
31. Raeburn D., Underwood S.L., Lewis S.A., Woodman V.R., Battram C.H., Tomkinson A., Sharma S., Jordan R., Souness J.E., Webber S.E., et al. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br. J. Pharmacol. 113 (1994) 1423-1431
32. Salez F., Gosset P., Copin M.C., Lamblin Degros C., Tonnel A.B., and Wallaert B. Transforming growth factor-beta1 in sarcoidosis. Eur. Respir. J. 12 (1998) 913-919
33. Saura M., Zaragoza C., Herranz B., Griera M., Diez-Marques L., Rodriguez-Puyol D., and Rodriguez-Puyol M. Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells. Circ. Res. 97 (2005) 1115-1123
34. Schiller M., Verrecchia F., and Mauviel A. Cyclic adenosine 3′,5′-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism. Oncogene 22 (2003) 8881-8890
35. Schmidt P., Schramm M., Schroder H., and Stasch J.P. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur. J. Pharmacol. 468 (2003) 167-174
36. Selman M., King T.E., and Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134 (2001) 136-151
37. Skutek M., van Griensven M., Zeichen J., Brauer N., and Bosch U. Cyclic mechanical stretching modulates secretion pattern of growth factors in human tendonfibroblasts. Eur. J. Appl. Physiol. 86 (2001) 48-52
38. Sousa A.M., Liu T., Guevara O., Stevens J., Fanburg B.L., Gaestel M., Toksoz D., and Kayyali U.S. Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2. J. Cell. Biochem. 100 (2007) 1581-1592
39. Stasch J.P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiss U., Schroder H., Schroeder W., Stahl E., Steinke W., Straub A., and Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 410 (2001) 212-215
40. Stratton R., Rajkumar V., Ponticos M., Nichols B., Shiwen X., Black C.M., Abraham D.J., and Leask A. Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J. 16 (2002) 1949-1951
41. Thompson W.J., and Appleman M.M. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv. Cycl. Nucleotide Res. 10 (1979) 69-92
42. Valente E.G., Vernet D., Ferrini M.G., Qian A., Rajfer J., and Gonzalez-Cadavid N.F. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 9 (2003) 229-244
43. Wojnarowski C., Frischer T., Hofbauer E., Grabner C., Mosgoeller W., Eichler I., and Ziesche R. Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation. Eur. Respir. J. 14 (1999) 1136-1144